Arkolith/Insider Trading/VKTX/Form 4

Zante Greg

Chief Financial OfficerViking Therapeutics, Inc. (VKTX) · full profile →Form 4 · filed Jan 6, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.2M
Net Open-Market Flow
-$2.2M
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2025Sell(S)5K$43.32$204K165K
Jan 6, 2025Sell(S)46K$42.69$1.9M170K
Jan 3, 2025Grant(A)45K—$0194K
Jan 3, 2025Grant(A)22K—$0216K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 3, 2025Grant(A)37K—$037K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-002485) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML